Thorough QT (TQT) clinical trial evaluating the effects of deutetrabenazine (SD 809) on cardiac repolarisation in healthy volunteers.

Trial Profile

Thorough QT (TQT) clinical trial evaluating the effects of deutetrabenazine (SD 809) on cardiac repolarisation in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Deutetrabenazine (Primary) ; Moxifloxacin; Tetrabenazine
  • Indications Chorea
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Auspex Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 20 Jan 2015 New trial record
    • 12 Jan 2015 Results published in an Auspex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top